Psychiatric Services
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Stein, B. D.
* Articles by Ringel, J.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Stein, B. D.
* Articles by Ringel, J.
Related Collections
* Child/Adolescent Psychiatry
* Atypical Neuroleptics
* Conventional Neuroleptics
* Antidepressants
* Anxiolytics
Psychiatr Serv 52:152, February 2001
© 2001 American Psychiatric Association


Columns

Datapoints: Psychotropic Medication Costs Among Youth With Private Insurance in 1998

Bradley D. Stein, M.D., M.P.H., Roland Sturm, Ph.D., Kanika Kapur, Ph.D. and Jeanne Ringel, Ph.D.


  Introduction

 
 TOP
 Introduction
 References
 
Recent studies have documented a substantial increase in the use of psychotropic medications by children and adolescents. Use of antidepressants by youths tripled between 1988 and 1996 (1), and similar increases have been seen in their use of other psychotropic medications (3). However, no data are available on the proportion of total mental health costs accounted for by use of psychotropic medications by youth.

This column presents 1998 cost estimates from more than 100,000 privately insured children in all census regions. Costs were calculated from claims data from 28 large employers. In 1998 mental health expenditures for children with private insurance totaled some $5.5 billion, excluding services provided by state and local agencies and not paid for by private insurance. Expenditures for psychotropic medications for children covered by private insurance were approximately $670 million, or 11.9 percent of total expenditures.

As Figure 1 shows, the proportion varied across age groups for children. About 4.3 percent of children received psychotropic medications, compared with 4.7 percent of adults (data not shown).



View larger version (30K):
[in this window]
[in a new window]
 

Figure 1. Cost of psychotropic medications as a percentage of total costs for mental health care among privately insured children, adolescents, and adults in 1998



As Figure 2 shows, stimulants were the most common medication prescribed in all age groups among children. Antidepressants accounted for 50 percent of the total costs for psychotropic medications among those aged 12 to 17, compared with 10 percent among one- to five-year-olds and 28 percent among children aged six to 11.



View larger version (21K):
[in this window]
[in a new window]
 

Figure 2. Use of psychotropic medications by privately insured children and adolescents in 1998



We found that both the rates of use of psychotropic medications and their costs were lower among children and adolescents than among adults, despite the increased use of these medications among youths. At the same time, psychotropic medications now represent an appreciable part of children's total mental health costs. Most of the cost for these medications are for the use of antidepressants by adolescents and stimulants by younger children.


  Footnotes

 
The authors are affiliated with Rand 1700 Main Street, Santa Monica, California 90407 ( bradley_stein{at}rand.org ).


  References

 
 TOP
 Introduction
 References
 

  1. Zito JM, Safer D, dosReis S, et al: Patterns of antidepressant use in youths with Medicaid insurance. Presented at the annual meeting of the American Academy of Child and Adolescent Psychiatry, Oct 24-29, 2000, New York
  2. Zito JM, Safer DJ, dosReis S, et al: Trends in the prescribing of psychotropic medications to preschoolers. JAMA 283:1025-1030, 2000[Abstract/Free Full Text]
  3. Zito JM, Safer DJ, dosReis S, et al: Psychotherapeutic medication patterns for youths with attention-deficit/hyperactivity disorder. Archives of Pediatrics and Adolescent Medicine 153:1257-1263, 1999[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
Psychiatr. Serv.Home page
D. Zatzick and P. P. Roy-Byrne
From Bedside to Bench: How the Epidemiology of Clinical Practice Can Inform the Secondary Prevention of PTSD
Psychiatr Serv, December 1, 2006; 57(12): 1726 - 1730.
[Abstract] [Full Text] [PDF]


Home page
Arch Pediatr Adolesc MedHome page
J. M. Zito, D. J. Safer, S. dosReis, J. F. Gardner, L. Magder, K. Soeken, M. Boles, F. Lynch, and M. A. Riddle
Psychotropic Practice Patterns for Youth: A 10-Year Perspective
Arch Pediatr Adolesc Med, January 1, 2003; 157(1): 17 - 25.
[Abstract] [Full Text] [PDF]


This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Stein, B. D.
* Articles by Ringel, J.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Stein, B. D.
* Articles by Ringel, J.
Related Collections
* Child/Adolescent Psychiatry
* Atypical Neuroleptics
* Conventional Neuroleptics
* Antidepressants
* Anxiolytics


Get information about faster international access.

Privacy Policy

Copyright © 2001 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org